checkAd

     105  0 Kommentare PolyPeptide publishes invitation to the annual General Meeting 2024 - Seite 2

    The invitation to the AGM 2024 with the detailed proposals and explanations can be found on the Company’s website.


    Contact

    PolyPeptide Group AG
    Michael Stäheli
    Head of Investor Relations & Corporate Communications
    michael.staeheli@polypeptide.com
    T: +41 43 502 05 80

     

    About PolyPeptide

    PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India.
    PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

    For more information, please visit polypeptide.com.  

    Lesen Sie auch

    @PolyPeptide – follow us on LinkedIn

     

    Disclaimer

    This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

    Seite 2 von 3



    EQS Group AG
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    PolyPeptide publishes invitation to the annual General Meeting 2024 - Seite 2 PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2024 19.03.2024 / 07:00 CET/CEST Media release PolyPeptide publishes invitation to the annual General Meeting 2024 Baar, 19 March 2024 – …